-
Mashup Score: 1
Show Beyond the Journal, Ep Dr. Jamie Von Roenn and Christopher Merlan, on ASCO’s Virtual Annual Meeting and the future of Digital Education | BTJ-004 – Dec 15, 2020
Source: Apple PodcastsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Adjuvant osimertinib extends DFS in localized NSCLC - 3 year(s) ago
Osimertinib reduced the risk of disease recurrence or death by 79% in patients with EGFR-mutated non–small cell lung cancer.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant osimertinib extends DFS in localized #NSCLC with Roy S. Herbst, MD, Ph.D., chief medical oncology at the @YaleCancer and @SmilowCancer at @Yale. #ASCO20 https://t.co/NycozVpvwh #OncoAlert #Cancer #ASCO2020 https://t.co/aMKv8JLhq6
-
-
Mashup Score: 3Moving on up: Maintenance therapy extends OS in bladder cancer - 3 year(s) ago
Avelumab maintenance after first-line chemotherapy is a new standard of care for advanced urothelial cancer, according to an investigator from the JAVELIN Bladder 100 trial.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
First-line maintenance therapy with an immune checkpoint inhibitor for patients with advanced bladder #cancer. https://t.co/WGyXGmeNWZ @ASCO #ASCO2020 #ASCO20 #OncoAlert #immunotherapy https://t.co/P0Ff4mQBhh
-
-
Mashup Score: 0TRAIN-2: Anthracyclines added toxicity, with no increased efficacy, in HER2+ breast cancer - 3 year(s) ago
Long-term results of TRAIN-2 suggest clinicians should “think carefully” before using anthracyclines in patients with HER2-positive disease.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO20: TRAIN-2, a randomized phase 3 trial suggests anthracyclines adds toxicity with no improved survival in patients with HER2-positive breast #cancer. https://t.co/xLww3nbBCT #ASCO2020 #medtwitter #Oncoalert #oncology @ASCO https://t.co/L4RTFeQZZ9
-
-
Mashup Score: 0PPI added to chemo improves breast tumor response rate - 3 year(s) ago
Omeprazole as an addition to treatment for triple-negative breast cancer boosted the expected rate of tumor disappearance in early-stage disease.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO20: PPI + chemo improves breast tumor response rates in phase 2 trial. https://t.co/pY5AmBev7i #ASCO2020 @ASCO #Oncoalert #cancer https://t.co/jdEYLEezGV
-
-
Mashup Score: 0Moving on up: Maintenance therapy extends OS in bladder cancer - 3 year(s) ago
Avelumab maintenance after first-line chemotherapy is a new standard of care for advanced urothelial cancer, according to an investigator from the JAVELIN Bladder 100 trial.
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
First-line maintenance therapy with an immune checkpoint inhibitor for advanced bladder #cancer. https://t.co/dzUUBjutYH @ASCO #ASCO2020 #ASCO20 #OncoAlert #immunotherapy https://t.co/RDat2qoKM4
-
-
Mashup Score: 0
An abstract is unavailable.
Source: LWWCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Virtual #ASCO2020 Meeting: #WednesdayWisdom from Dr. George Sledge, Jr. https://t.co/syrB3YOMPb #cancertreatment #research #medtwitter via @ASCO https://t.co/zgHt10iQmi
-
-
Mashup Score: 4Vivek Subbiah, MD on RET inhibitorr: Advanced in the Study @VivekSubbiah #ASCO2020 @MDAndersonNews #ASCO - 4 year(s) ago
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Read here: https://meetinglibrary.asco.org/record/186874/abstract
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses clinical activity of RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. #ASCO2020 #ASCO https://t.co/nZSpBTNHBB https://t.co/qFz42zFYBK
-
-
Mashup Score: 3Eric Jonasch, MD @MDAndersonNews #ASCO2020 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease @EJonasch - 4 year(s) ago
Eric Jonasch, MD @MDAndersonNews #ASCO2020 gives an overview of the Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease Bottom line: Von Hippel-Lindau disease (VHL) patients (pts) are at risk for multiple cancers including strong renal cell carcinoma (ccRCC). VHL inactivation results in constitutive activation of the transcription factor HIF-2α, which induces…
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Eric Jonasch, MD @MDAndersonNews #ASCO2020 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease @EJonasch https://t.co/1Ew5UMp0hu
-
-
Mashup Score: 0Blood & Cancer | MDedge - 4 year(s) ago
A twice-weekly podcast bringing you the latest news on Tuesdays and interviews with hematology/oncology experts on Thursdays. …
Source: www.mdedge.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Listen to the Best of ASCO 2020 on MDedge’s Blood & Cancer podcast with @davidhenrymd, and @Nick_Andrews__. https://t.co/E96Lj1LHzQ #ASCO2020 #LexPodcast #MDedge https://t.co/Ib0Lx3Z6XH
-
What is the future of Oncology Meetings? Catch up w/ Dr. Jamie Von Roenn & Christopher Merlan, on @ASCO's Virtual Meeting and the future of Digital Education on our next episode of #BeyondTheJournal @JackWestMD https://t.co/Cecsu9SVVB #ASCO2020 @AACR @IASLC @myESMO https://t.co/fkbZGOpQyG